阿托伐他汀对AECOPD患者血清GM-CSF及肺功能的影响
发布时间：2018-07-24 17:07
【摘要】：目的：探讨阿托伐他汀对慢性阻塞性肺疾病急性加重期(Acute exacerbation ofchronic obstructive pulmonary disease, AECOPD)患者血清粒细胞-巨细胞集落刺激因子（granulocyte-macrophage colony-stimulating factor，GM-CSF）水平及肺功能的影响。 方法：选择2012年04月到2013年01月住院的44例AECOPD患者，将其随机分为对照组(20例)和治疗组(24例)。对照组按照诊疗常规予以AECOPD常规治疗,治疗组在常规治疗基础上加用阿托伐他汀20mg，每日一次口服。两组均于入院第1天和治疗14天行肺功能测定,并收集血清GM-CSF,采用ELISA方法测定血清GM-CSF的含量，最后对所得数据进行统计学分析：采用SPSS19.0统计学软件进行数据处理，数据用x±s表示，两组治疗比较采用独立样本t检验，，治疗前后的2个变量间的关系比较采用配对t检验，血清GM-CSF与FEV1%pre水平采用直线相关分析，检验水准α=0.05。 结果：1）治疗组及对照组治疗14天后FEV1%pre较治疗前均显著升高(P0.01)；2）治疗组及对照组治疗14天后血清GM-CSF均较治疗前显著降低(P0.01)；3）AECOPD患者血清GM-CSF与FEV1%pre呈负相关(P0.01)；4）治疗组与对照组相比较治疗14天后FEV1%pre、血清GM-CSF水平无显著差异，无统计学意义(P0.05)。 结论：AECOPD患者经过治疗后血清GM-CSF的水平较前降低，肺功能较前好转，肺功能的改善可能与血清GM-CSF的水平的恢复有关。阿托伐他汀短期内未能明显降低AECOPD患者血清GM-CSF的水平，改善肺功能，有待于今后对稳定期COPD患者进行临床观察研究。
[Abstract]:Aim: to investigate the effects of Atto vastatin on serum granulocyte-giant cell colony-stimulating factor (GM-CSF) levels and pulmonary function in patients with acute exacerbation of chronic obstructive pulmonary disease (Acute exacerbation ofchronic obstructive pulmonary disease, AECOPD). Methods: 44 patients with AECOPD were randomly divided into control group (n = 20) and treatment group (n = 24). The control group was treated with AECOPD according to the routine treatment routine, and the treatment group was treated with 20 mg of Atto vastatin once a day on the basis of routine treatment. Lung function was measured on the first day of admission and 14 days after treatment. Serum GM-CSF was collected and serum GM-CSF content was measured by ELISA method. Finally, the data were analyzed statistically: the data were processed by SPSS19.0 software. The data were expressed as x 卤s, the two groups were treated with independent sample t test, the relationship between two variables before and after treatment was matched t test, the serum GM-CSF and FEV1%pre levels were analyzed by linear correlation analysis, the test level was 伪 0.05. Results (1) after 14 days of treatment, FEV1%pre in the treatment group and control group was significantly higher than that before treatment (P0.01). The serum GM-CSF in the treatment group and control group was significantly lower than that in the control group after 14 days of treatment (P0.01). There was a negative correlation between serum GM-CSF and FEV1%pre in the AECOPD patients (P0.01). 4) there was no significant difference in serum GM-CSF level between the treatment group and the control group after 14 days of treatment (P0.05). Conclusion after treatment, the level of serum GM-CSF and pulmonary function were decreased and the improvement of pulmonary function might be related to the recovery of serum GM-CSF. Atto vastatin could not significantly reduce the level of serum GM-CSF and improve pulmonary function in patients with AECOPD in a short time. The clinical observation and study of stable COPD patients were needed in the future.
【学位授予单位】：青海大学
【学位级别】：硕士
【学位授予年份】：2013
【分类号】：R563
本文编号：2142064
[Abstract]:Aim: to investigate the effects of Atto vastatin on serum granulocyte-giant cell colony-stimulating factor (GM-CSF) levels and pulmonary function in patients with acute exacerbation of chronic obstructive pulmonary disease (Acute exacerbation ofchronic obstructive pulmonary disease, AECOPD). Methods: 44 patients with AECOPD were randomly divided into control group (n = 20) and treatment group (n = 24). The control group was treated with AECOPD according to the routine treatment routine, and the treatment group was treated with 20 mg of Atto vastatin once a day on the basis of routine treatment. Lung function was measured on the first day of admission and 14 days after treatment. Serum GM-CSF was collected and serum GM-CSF content was measured by ELISA method. Finally, the data were analyzed statistically: the data were processed by SPSS19.0 software. The data were expressed as x 卤s, the two groups were treated with independent sample t test, the relationship between two variables before and after treatment was matched t test, the serum GM-CSF and FEV1%pre levels were analyzed by linear correlation analysis, the test level was 伪 0.05. Results (1) after 14 days of treatment, FEV1%pre in the treatment group and control group was significantly higher than that before treatment (P0.01). The serum GM-CSF in the treatment group and control group was significantly lower than that in the control group after 14 days of treatment (P0.01). There was a negative correlation between serum GM-CSF and FEV1%pre in the AECOPD patients (P0.01). 4) there was no significant difference in serum GM-CSF level between the treatment group and the control group after 14 days of treatment (P0.05). Conclusion after treatment, the level of serum GM-CSF and pulmonary function were decreased and the improvement of pulmonary function might be related to the recovery of serum GM-CSF. Atto vastatin could not significantly reduce the level of serum GM-CSF and improve pulmonary function in patients with AECOPD in a short time. The clinical observation and study of stable COPD patients were needed in the future.
【学位授予单位】：青海大学
【学位级别】：硕士
【学位授予年份】：2013
【分类号】：R563
【参考文献】
相关期刊论文 前9条
1 王月州;;COPD患者治疗前后血清NO、NOS和GM-CSF检测的临床意义[J];放射免疫学杂志;2011年06期
2 王媛媛;李国平;;粒细胞-巨噬细胞集落刺激因子在COPD中的研究进展[J];西南军医;2012年01期
3 白春学;COPD的炎症和抗炎研究进展[J];临床肺科杂志;2005年05期
4 王永彬;王伟;;辛伐他汀对COPD患者细胞凋亡和炎症因子的干预作用[J];山东大学学报(医学版);2009年08期
5 陈旭东;王伟;王永彬;;辛伐他汀对COPD大鼠模型炎症的干预作用[J];山东大学学报(医学版);2010年04期
6 杨永华;陈炯;;粒细胞巨噬细胞集落刺激因子在创面愈合中的应用进展[J];实用医学杂志;2008年19期
7 张平;李卫东;;辛伐他汀对慢性阻塞性肺疾病大鼠肿瘤坏死因子-α表达的影响及机制[J];中国药物与临床;2010年04期
8 仝重芳;李卫东;赵卉;岳翠萍;张敏艳;;辛伐他汀对慢性阻塞性肺疾病大鼠白细胞介素-6基质金属蛋白酶-9表达的影响[J];中国药物与临床;2011年03期
9 夏书月;康健;何巍;许晓阳;何晓琳;王实;;辛伐他汀对COPD急性加重期患者诱导痰血管内皮生长因子水平和肺功能的影响[J];中国呼吸与危重监护杂志;2010年03期
本文编号：2142064
本文链接：https://www.wllwen.com/yixuelunwen/huxijib/2142064.html
最近更新
教材专著
